Item 5.02 Departure of Directors or Certain Officers; Election of Directors;


          Appointment of Certain Officers; Compensatory Arrangements of Certain
          Officers.

On March 26, 2020, the Board of Directors (the "Board") of Alexandria Real Estate Equities, Inc. (the "Company") elected Jennifer Friel Goldstein as a director of the Company, to serve until the 2020 annual meeting of stockholders of the Company and until her successor is duly elected and qualifies. The Board also appointed Ms. Goldstein as a member of its Science and Technology Committee and has determined that Ms. Goldstein is independent in accordance with applicable New York Stock Exchange listing standards and Securities and Exchange Commission rules. There were no arrangements or understandings between Ms. Goldstein and any other persons regarding her election to the Board. Ms. Goldstein is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Ms. Goldstein is the head of Business Development, Technology and Healthcare
Silicon Valley Bank ("SVB"). She is responsible for business development,
venture capital relationship management and corporate relationship management
across all sectors for the bank.
Prior to joining SVB in 2012, Ms. Goldstein served on Pfizer Inc.'s Venture
Capital team, during which time she helped lead or co-lead fund-of-fund
investment decisions and manage Pfizer's private equity portfolio. She has also
served as a consultant at Bain & Company in London where she focused on private
equity transactions across Europe. Additional experience at companies such as
Chiron, Genelabs and Genencor further developed Ms. Goldstein's diverse
operational and research skills.
Ms. Goldstein also serves on the board of the Leukemia and Lymphoma Society in
Silicon Valley. She graduated magna cum laude with a Bachelor of Science in
Engineering degree in Bioengineering and a Master of Biotechnology from the
University of Pennsylvania. Ms. Goldstein was also named a Joseph Wharton Fellow
while completing her MBA at the Wharton School.
On her initial election to the Board and pursuant to the terms of the Company's
Amended and Restated 1997 Stock Award and Incentive Plan, Ms. Goldstein received
a grant of 1,000 shares of restricted stock of the Company, which shares vest in
full on the second anniversary of the date of grant. Ms. Goldstein will also
generally participate in the compensation arrangements provided to the Company's
independent directors, as described in the Company's Definitive Proxy Statement
on Schedule 14A, filed with the Securities and Exchange Commission on April 9,
2019, under the caption "2018 Director Compensation Table."

The press release announcing Ms. Goldstein's election as a director of the Company is attached hereto as Exhibit 99.1 and is filed herewith.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits


  99.1 Press Release, dated March 27, 2020.
104.1        Cover Page Interactive Data File - the cover page XBRL tags are
             embedded within the Inline XBRL document.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses